RxDoctor Payments Data

Ken Melchionna, DO

Ophthalmology · Dundee, ILNPI 1982660866

Payments from drug & device makers

$912in general payments, 2019–2025

Across 44 payments — averaging $20.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$305
  • Alcon$294
  • NEW World Medical,inc.$76
  • Aerie Pharmaceuticals, Inc.$69
  • Sun Pharmaceutical Industries Inc.$40
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$37
  • plus $92 from 5 others

What the payments were for

  • Food & beverage$912100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$912 in reported general payments places this provider in the 40th percentile of 773 ophthalmology providers in Illinois.

See all ophthalmology providers in Illinois

Medicare billing

Part B allowed, 2024
$204,777
Medicare patients
658
Services billed
2,369

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost174$82,519
RestasisCyclosporine33$49,358
RhopressaNetarsudil Mesylate25$16,796
Alphagan PBrimonidine Tartrate46$13,792
RocklatanNetarsudil Mesylat/Latanoprost22$13,297
Brimonidine Tartrate103$13,249
Travoprost64$9,880
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol44$7,997
CombiganBrimonidine Tartrate/Timolol20$7,613
VyzultaLatanoprostene Bunod18$6,612
Latanoprost458$5,118
Cyclosporine18$3,627
Timolol Maleate223$2,209
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat82$1,164
Pilocarpine Hcl23$1,046

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Alphagan P, Combigan$305$153,282273 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$69$30,09447 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 773 ophthalmology providers in Illinois.

Other ophthalmology in Dundee

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →